Recent Updates
Recently added Catalysts
GH Positive Sentiment

Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening

Monday, September 14, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Guardant Health announced that its Shield blood test for colorectal cancer screening will be covered by EviCore by Evernorth, effective January 1, 2027. This decision follows the American Cancer Society guidelines and signifies a notable expansion in the test's commercial adoption. EviCore, a major specialty benefits manager, operates in over 23 states.

Market Sentiment Analysis

POSITIVE FACTORS

  • Guardant Health's Shield blood test gains coverage for CRC screening.
  • Coverage aligns with ACS guidelines, enhancing credibility.
  • EviCore's extensive reach increases accessibility for patients.

Full Press Release Details

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) will be covered in EviCore by Evernorth clinical guidelines effective January 1, 2027, per ACS guidelines. EviCore is a Cigna-owned company and the second largest specialty benefits manager in the country spanning more than 23 states. The latest policy update from Shield marks a rapid growth in commercial adopt

Frequently Asked Questions

What is the Shield blood test?

The Shield blood test is a screening tool for colorectal cancer developed by Guardant Health.

When will EviCore coverage for the Shield test begin?

EviCore coverage for the Shield blood test will start on January 1, 2027.

Who owns EviCore?

EviCore is owned by Cigna and is a major specialty benefits manager.

What guidelines does the Shield test follow?

The Shield blood test follows the guidelines set by the American Cancer Society.

ShareAdd on Google
Tags: GH Viatris Investor Conferences Healthcare Guardant Health Shield blood test colorectal cancer EviCore Cigna
Last updated: Sep 14, 2026

Biotech snapshot

Cash runway
$1053M liquidity · $19M/mo burn
~53 mo
Minimal dilution risk